You have played a major part in improving Huntington’s disease patients’ quality of life

Volunteers who participated in QCL113049, a human ADME study which we conducted back in 2012-2013, might be pleased to know that the molecule has just been approved as a treatment for Chorea associated with Huntington’s disease.

Chorea is the most visible feature of Huntington’s disease and it is characterised by abnormal, irregular, ‘dance-like’ movements. It is noted that nine out of ten people with Huntington’s disease will develop chorea at some point as their illness progresses.

As a volunteer in this study, you have played a major part in improving Huntington’s disease patients’ quality of life.

Thank you for your continuous support.

To browse current clinical trials, click here.